What is Withings ScanWatch?

Withings: hybrid analog watch archetype + independent French biometric company

Withings is an independent French biometric wearable company with current product line spanning ScanWatch + ScanWatch 2 + ScanWatch Nova. Per DEPLOY's biometric cluster framework, Withings anchors the hybrid analog watch archetype: mechanical-digital design distinct in the cohort + substantial-cleared-for-size FDA posture + cohort-mature peer-reviewed validation depth.

---

Corporate history: French independence

Withings's institutional history is editorially substantive at the corporate-strategy layer:

• Founded as Withings in France (Issy-les-Moulineaux); biometric wearable + connected health products from inception.
• Acquired by Nokia 2016: Nokia's brief entry into consumer health wearables; product line rebranded as Nokia Health for a period.
• Bought back by founder Eric Carreel 2018: independent operation restored under original founder leadership; rebranded back to Withings.
• Current status: independent French biometric company; not part of larger corporate parent group.

The independent French status distinguishes Withings from cohort peers operating under larger corporate parents (Fitbit + Pixel Watch under Google; Apple Watch under Apple; Samsung Galaxy Watch under Samsung). Per DEPLOY's framework, corporate-structure positioning is editorial signal at the cohort-positioning layer.

---

FDA portfolio: ECG cleared 2021 EU / OTC 2025 US + SpO2

Withings carries substantive cleared scope with notable EU vs US clearance gradient:

• ECG cleared 2021 (EU): ScanWatch line ECG functionality cleared in European Union 2021; CE marking + IFU coverage at EU regulatory tier.
• ECG OTC 2025 (US): ECG functionality OTC clearance in US 2025 (recent clearance); cap-flag on US-vs-EU clearance timeline differential.
• SpO2 monitoring: blood oxygen tracking across ScanWatch line; positioned at wellness-grade.
• Adjacent feature clearances: AFib detection; sleep apnea screening in cleared markets.

Per DEPLOY's verified-vs-claimed framework, the EU vs US clearance gradient is editorial signal: ECG clearance landed in EU 2021 + OTC 2025 in US (4-year clearance-timeline gap). The gradient demonstrates that cohort manufacturer FDA strategies vary by market; US OTC pathway has different timeline than EU CE marking for ECG features.

---

Product + business model

Current product line (2026): ScanWatch + ScanWatch 2 + ScanWatch Nova. The ScanWatch line is the hybrid mechanical-digital design archetype: traditional analog watch face with embedded digital biometric sensors + small OLED display for digital metrics. Distinct in cohort from pure-digital displays (Apple Watch + Pixel Watch + Samsung Galaxy Watch + Garmin smart-watch lines) and ring form factors (Oura + RingConn + Ultrahuman).

Pricing: ScanWatch line mid-tier pricing across the SKU range; purchase + optional subscription model alongside Fitbit + Pixel Watch. Withings+ subscription (optional) unlocks advanced health insights and Apple Health + Google Fit integrations. Verified consumer pricing transparency for the ScanWatch line lives at Withings ScanWatch pricing on the consumer surface.

---

Validation evidence + cohort positioning

Cohort-mature peer-reviewed validation depth across cardiac + sleep + SpO2 metrics. The mature validation base reflects multi-year European clinical validation studies + US OTC clearance pathway depth. Per DEPLOY's verified-vs-claimed framework, Withings's validation depth positions the brand at substantial-cleared-for-size archetype: substantive validation evidence at hybrid analog watch form factor that distinguishes the line in cohort.

---

Cohort positioning + contrasts

Per the biometric cluster framework, Withings anchors:

• Hybrid analog watch archetype: mechanical-digital design distinct in cohort.
• Substantial-cleared-for-size: substantive FDA portfolio at hybrid analog form factor; not just smart-watch or ring.
• Independent French corporate structure: distinct from cohort peers under larger corporate parents.
• EU vs US clearance gradient documented: ECG 2021 EU + OTC 2025 US; cap-flag on market-clearance timeline differentials.

Contrast with cohort:

• Apple Watch: substantial-cleared at $249-$799+; pure-digital form factor; broader feature portfolio + largest validation base.
• Pixel Watch: first-of-kind-cleared; Google parent; pure-digital form factor.
• Fitbit: budget-tier cleared; Google product line; pure-digital form factor.
• Garmin: lighter-cleared; athletics-primary; pure-digital sports watch form factor.
• Samsung Galaxy Watch: Korean parent; pure-digital form factor; Korea + EU vs US clearance gradient.
• Oura + Whoop: ring + band form factors; structurally distinct cell.
• Dexcom Stelo: glucose-biometric cell; structurally distinct sensor modality.

For the canonical biometric cohort context, see the biometric cluster. For adjacent AI wearables cohort context, see what is an AI wearable. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Withings: verified-vs-claimed at within-entity granularity (within-Withings ScanWatch ECG cleared + Class-2 recall verification posture distinct from BPM Core blood pressure scope) + the 9-tier source-quality rubric (FDA + CPSC + Withings IR primary-government-record source classification).